Dr. Grupp develops and conducts preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. Dr. Grupp leads most CTL019 (CD19 CAR) clinical trials, and his colleagues are the global leaders in highly active CAR T cell therapy.
It was a pivotal moment that has turned into a new era for cancer immunotherapy. On April 17, 2012, Children's Hospital of Philadelphia researchers for the first time treated a pediatric patient with a cellular therapy that used her own reprogrammed immune cells, called T cells, to attack her aggressive form of blood cancer.
From cancer drugs designed to match a child's specific molecular abnormality, to a phone app that can offer a dermatologic diagnosis quicker than an office visit, the future of children's healthcare is unfolding right before our eyes at the Children's Hospital of Philadelphia Research Institute.
CAR T-cell therapy tops this week's research roundup, with news about the experimental immunotherapy designed to re-engineer a patient's cells to fight cancer making late-breaking and captivating headlines across the nation.
Our latest research news roundup carries a hint of summer and exciting new beginnings: As more than 70 Children's Hospital of Philadelphia experts traveled to sunny California for the annual Pediatric Academic Societies (PAS) Meeting, back at home, sports medicine research ramped up with new investigations into how we can protect kid's health on (and off) the field.
A simple question raised by a concerned parent can often kick-start lines of research at Children's Hospital of Philadelphia. This week in the news, those sorts of everyday queries - whether they're about how to breastfeed, why parents should follow a vaccine schedule, or how mechanical circulatory support devices work - led to exciting headline-making stories.